You are viewing the site in preview mode
Skip to main content
|
Study subgroup (number of studies)
|
Subgroup
|
Comparison group
|
P value for interaction
|
|---|
|
Odds ratio, (95% CI)
|
|
Statin prescribing (11)
|
|
More than 2 implementation strategies (6)
|
2.19 (1.32–3.63)
|
2.40 (1.43–4.06)
|
0.80
|
|
Study published in 2013 or later (5)
|
1.97 (1.29–3.01)
|
2.84 (1.41–5.74)
|
0.36
|
|
Conducted in the United States (2)
|
4.00 (1.03–15.50)
|
1.95 (1.33–2.84)
|
0.32
|
|
LDL-C (14)
|
|
More than 2 implementation strategies (4)
|
1.53 (1.23–1.90)
|
1.20 (0.97–1.48)
|
0.12
|
|
Study published 2013 or later (5)
|
1.62 (1.19–2.19)
|
1.13 (0.95–1.35)
|
0.05
|
|
Conducted in the United States (5)
|
1.48 (1.12–1.95)
|
1.29 (1.03–1.61)
|
0.35
|
|
Standardized mean difference, (95% CI)
|
|
LDL-C (17)
|
|
More than 2 implementation strategies (6)
|
− 0.38 (− 0.67; − 0.09)
|
− 0.07 (− 0.15; − 0.01)
|
0.05
|
|
Study published in 2013 or later (8)
|
− 0.12 (− 0.21; v0.02)
|
− 0.23 (− 0.39; − 0.07)
|
0.24
|
|
Conducted in the United States (6)
|
− 0.20 (− 0.36; − 0.04)
|
− 0.17 (− 0.31; − 0.03)
|
0.79
|
- Statin adherence was excluded because there were not enough studies to make a comparison
